Navigation Links
ARIUS presents new findings for anti-cancer antibody programs at AACR
Date:4/15/2008

-ARIUS report new data and program updates on cancer stem cell targeting

antibodies-

TORONTO, April 15 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced that it will be presenting new findings and program updates related to its CD44, TROP-2, CD59, and CD9 antibody programs at the American Association for Cancer Research (AACR) Annual Meeting held from April 12-16, 2008 in San Diego, California.

"Our five presentations at AACR shows the tremendous progress we made over the last year with our lead programs. The new findings from our cancer stem cell programs targeting CD44 and CD9 are of particular interest to the scientific community as this is a promising new area of cancer research," said Dr. David Young, President and CEO of ARIUS. "Specifically, we have been able to demonstrate that our CD44 program has the potential for wide therapeutic application in solid tumors, as well as blood cancers. Our cancer stem cell antibody targeting CD9 differentially recognizes AML cancer stem cells compared to normal stem cells. Furthermore, treatment with this antibody can functionally reduce cancer stem cell self-renewal which has very important therapeutic implications."

CD44 Cancer Stem Cell Program

Preclinical development of huARH460-16-2, a humanized antibody to the CD44 cancer stem cell target. Abstract Number 3975. Experimental and Molecular Therapeutics 32, Tuesday, April 15, 2008, 8:00 AM

ARIUS' ARH460-16-2, a functional antibody that targets CD44, has a new potential cancer indication for pancreatic cancer. The new findings show anti-tumor effects in an established BxPC3 human pancreatic cancer model (78.7% tumor growth inhibition at 2 mg/kg compared to control group). This antibody has broad effects in solid tumors since it have been shown to be effective in pancreatic, breast, live
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ARIUS announces first quarter fiscal 2008 financial results
2. ARIUS 2008 Annual and Special Meeting of Shareholders
3. ARIUS recognized for entrepreneurial excellence
4. ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
5. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
6. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
7. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
8. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
9. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
10. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
11. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 2013 was a banner ... State Technologies®. They saw continued independent research led by ... were awarded a $1 million grant from the Susanne ... and Behavior” a peer reviewed journal, Amy Grant highlighted ...
(Date:1/15/2014)... 2014 AudioNotch is the internet's leading ... the treatment of tinnitus. Patients listen to sound therapy ... a period of weeks to months, their tinnitus volume decreases. ... forms: Notched Music and Notched White Noise. Now, AudioNotch is ...
(Date:1/14/2014)... January 14, 2014 Date: Friday, April 11, ... Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... organization solely dedicated to finding a cure for hepatitis B ... will host its annual Crystal Ball on Friday, April 11 ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company ... under simulated embryonic conditions, today announced that they have ... Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent ... is an amendment to the existing license between Histogen ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... Therapies to Address the Underlying Cause of Cystic,Fibrosis; ... SOUTH PLAINFIELD, N.J., Aug. 20 New ... that the investigational oral drug,PTC124 demonstrates activity in ... with PTC124 results in statistically significant,improvements in the ...
... Oncothyreon Inc. (Nasdaq:,ONTY) (TSX: ONY) announced today that ... on August 14, 2008 indicating that Oncothyreon does ... The NASDAQ Global Market,because it does not meet ... (i) the market value of Oncothyreon,s common stock ...
... Crystal Research Associates, LLC,announced today that ... on Generex Biotechnology Corporation (Nasdaq: GNBT ... at http://www.crystalra.com ., Generex Biotechnology ... pharmaceutical company that aims to research, develop, ...
Cached Biology Technology:PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet 2PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet 3PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet 4PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet 5Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market 2Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market 3Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation 2Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation 3
(Date:4/22/2014)... of Yale researchers will lead a five-year, $3 million ... events is affecting the transport of dissolved organic matter ... say could alter the chemical composition and water quality ... funding from the National Science Foundation,s MacroSystems Biology program, ... the watershed, which begins in Canada and runs through ...
(Date:4/22/2014)... fist-like club of a mantis shrimp, a team of ... with University of Southern California and Purdue University, have ... more impact resistant and tougher than the standard used ... of this tiny crustacean, the more we realize its ... day," said David Kisailus, a Kavli Fellow of the ...
(Date:4/22/2014)... The Federation of American Societies for Experimental Biology (FASEB) ... (FY) 2013 highlighting how funding from the National Institutes ... DC, and Puerto Rico. "FASEB is pleased to make ... the significance of NIH to their state," said FASEB ... nation,s leading source for biomedical research funding, investing ...
Breaking Biology News(10 mins):Connecticut River watershed study will assess impacts of extreme rain events 2Connecticut River watershed study will assess impacts of extreme rain events 3Mantis shrimp stronger than airplanes 2Mantis shrimp stronger than airplanes 3
... of children with undiagnosed learning disorders, developmental deficits, and ... challenges, which are explored in detail in a reflective ... a peer-reviewed journal published by Mary Ann Liebert, Inc. ... ahead of print at www.liebertpub.com/gtmb ...
... been extinct for 65 million years, newly published data ... is providing invaluable insights into their paleobiology. Ammonites, shelled ... inhabited the oceans for nearly 350 million years. Specimens ... that covered North America during the Cretaceous Period demonstrate ...
... are investigating a potential new treatment for lung disease that ... is studying how statins, drugs which are commonly used to ... , There is currently no effective treatment for acute ... rates for those who become critically ill and suffer lung ...
Cached Biology News:Unexplained childhood disorders 2New discoveries in North America's Great Plains bring ammonites to life 2New discoveries in North America's Great Plains bring ammonites to life 3Queen's University Belfast lung injury study could save lives in critically ill 2